NSCLC Targeted Therapy: EGFR Exon 20 Mutation

An expert oncologist and a patient advocate work together to discuss the importance of EGFR exon20 treatment in metastatic non-small cell lung cancer.

EP. 1: Overview of EGFR Exon 20 and Molecular Testing in NSCLC

April 29th 2022

Experts explain the presence and role of EGFR exon 20 insertion mutations in non–small cell lung cancer and highlight the role of molecular profiling.

EP. 2: The Importance of Molecular Profiling and Patient Education in NSCLC

April 29th 2022

Shared insight on how molecular profiling can impact the management of EGFR exon 20 insertion–positive NSCLC and how patient advocacy groups can help patients to interpret test results.

EP. 3: Access to Novel Therapy for EGFR Exon 20–Positive NSCLC

May 6th 2022

A brief discussion on the importance of accessing novel therapy and clinical trials in the setting of EGFR exon 20 insertion–positive NSCLC.

EP. 4: Use of Amivantamab in patients with EGFR Exon 20–Positive Non–Small Cell Lung Cancer

May 6th 2022

An expert in the lung cancer and a representative from lung cancer advocacy group talk about the use of amivantamab, a novel therapy approved for treating EGFR exon 20 insertion–positive disease.

EP. 5: How to Decide on Novel Therapy for EGFR Exon 20–Positive NSCLC

May 13th 2022

Looking at available novel therapy for EGFR exon 20 insertion–positive NSCLC, experts consider how patients can play a part in identifying their best treatment option.

EP. 6: Support for Patients Undergoing Treatment for NSCLC

May 13th 2022

Comprehensive discussion on support for patients receiving therapy for NSCLC, ranging from care team members to education materials to support groups.

EP. 7: Improving Quality of Life While Receiving Treatment for NSCLC

May 20th 2022

A focused conversation on how a patient can maintain and improve quality of life while receiving therapy for non–small cell lung cancer.

EP. 8: Enrolling in Clinical Trials for EGFR Exon 20–Positive NSCLC

May 20th 2022

A shared discussion on the importance of enrolling in clinical trials for EGFR exon 20–positive NSCLC and improving access to novel therapy for patients.

EP. 9: Unmet Needs in the Management of EGFR Exon 20–Positive NSCLC

May 27th 2022

Before closing out their discussion on treatment for EGFR Exon 20–Positive NSCLC, experts discuss prominent unmet needs in this setting.